- Optimi Health (OPTI) has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility
- The initial batch of Optimi’s natural psilocybin mushrooms is intended specifically for analysis and use in human clinical trials
- Optimi has received a Section 56 Exemption to the Controlled Drugs and Substances Act from Health Canada in order to carry out research to establish a safe and effective standardized microdose of psilocybin for mental health conditions
- Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets
- Optimi Health Corp. (OPTI) is up 8.2 per cent on the day, trading at C$0.33 per share at 10:30 am ET
Optimi Health (OPTI) has commenced the cultivation of natural GMP-grade psilocybin mushrooms at its Princeton, British Columbia facility.
“These mushrooms are an important milestone in Optimi’s commitment to establishing a supply of safe, natural psilocybin products for use by approved parties engaged in clinical trials,” said Optimi Health CEO Bill Ciprick.
“Since the completion of our 20,000 square foot cultivation and processing facilities and the approval of our Controlled Drugs and Substances Dealers License by Health Canada, Optimi has pressed forward with the goal of generating revenue and demonstrating a system of safe supply that can scale with the needs of the sector while participating in research crucial to the advancement of psychedelic science.”
The initial batch of Optimi’s natural psilocybin mushrooms is intended specifically for analysis and use in human clinical trials where market demand for natural psilocybin is increasing.
Optimi is partnering with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary and has opted to assess its product prior to completion of the company’s clinical trial application.
Optimi has received a Section 56 Exemption to the Controlled Drugs and Substances Act from Health Canada in order to carry out its own research to determine a safe and effective standardized microdose of psilocybin for mental health conditions such as anxiety and depression.
Optimi Executive Chairman, JJ Wilson, adds that today’s announcement is a “momentum building” milestone that speaks to the company’s goal of becoming a world supplier in the cultivation and formulation of natural psilocybin.
“The Optimi team is 100 per cent committed to helping the world deal with the concurrent crises of mental health and aging with safe, sustainable supplies of an organic product that has been used medicinally since time immemorial,” said Wilson.
“We will share more about our mission and vision over the coming weeks and months; however, for now, we’ll go back to the lab where our goal is to produce the quality and scale needed to meet the global demand for natural psilocybin.”
Optimi plans to showcase its new GMP facility at a brand and media launch in May.
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets.
Optimi Health Corp. (OPTI) is up 8.2 per cent on the day, trading at C$0.33 per share at 10:30 am ET.
